摘要
目的 探讨奥利司他(Orlistat,赛尼可)对肥胖糖耐量低减(IGT)患者的干预效果。方法 患者随机分两组奥利司他治疗组(50例)和对照组(51例),治疗为期1年,于治疗前后测量血脂、口服糖耐量试验(OGTT)、体重、身高等指标。结果1年后,治疗组上述指标明显改善(P<0.01),其恶化为糖尿病的发病率明显低于对照组(P<0.01)。结论 在肥胖IGT干预治疗中,奥利司他加饮食和运动治疗后可使体重减轻,改善糖耐量,明显减少糖尿病的发生。
Objective To discuss the preventive effect of Orlistat on the fatty patients with impaired glucose tolerance (IGT). Meth-
ods The patients, which had been divided into Orlistat group 50 cases socases and comparison group randomly 51 cases, were trealed
for one year. The index, such as blood-lipid, oral glucose tolerance test (OGTT), weight, height, etc. were measured before and after
the treatment. Result After one year's treatment, the above index of Orlistat group were improved evidently(P < 0. 01), and the diabe-
tes incidence of Orlistat group was much more lower than the comparison group (P<0.01). Conclusion On the treatment of fatty
IGT, Orlistat with diet and exercise can loss weight, improve glucose tolerance, reduce diabetes incidence evidently.
出处
《广东药学》
2004年第3期40-41,共2页
Guangdong Pharmaceutical Journal
基金
广州市黄埔区科技项目(2002埔科13号)
